p53 genetic abnormalities and myc activation in human lung carcinoma
- 17 July 1994
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 58 (1), 24-32
- https://doi.org/10.1002/ijc.2910580106
Abstract
p53 mutations and myc gene amplification and expression were studied in 119 lung carcinomas of all histological types. A mutant p53 immunophenotype was previously found in 47% of these tumors by immunohistochemical analysis. Seven cases exhibited p53 genomic rearrangements on Southern blots. Elevated levels of p53 transcript were found in 12 carcinomas (10%) and decreased levels in 27 carcinomas (23%) on Northern blots. In most of the cases, low levels of transcript were associated with negative immunostaining, whereas elevated levels of mRNA were related to positive immunostaining (mutant immunophenotype). p53 RT/PCR analysis in 10 tumors with absence of transcript on Northern blots revealed only weak or absent expression of normal and/or altered size transcripts. These abnormal transcripts showed deletions, insertions or splicing abnormalities. Taken together, p53 abnormalities were found in 66% of lung carcinomas [52% of neuroendo‐crine (NE) carcinomas and 75% of NSCLC]. c‐myc was found to be activated in 24% (10/42) of these NE and in 48% (33/69) of these NSCLC carcinomas using Southern‐ and Northern‐blot techniques. In addition, L‐ and N‐myc genes were also activated in 26% (10/42) of NE carcinomas. No correlation was found between p53 mutations and myc activation in SCLC or in NSCLC, but their association was significantly more frequent in NSCLC than in SCLC. These results indicate that the p53‐positive immunophenotype uncovers the occurrence of p53 point mutations in lung cancer and that p53 and c‐myc gene alterations are important but represent independent occurrences in the development of lung tumors.Keywords
This publication has 10 references indexed in Scilit:
- Overexpression of the p53 Tumor Suppressor Gene Product in Primary Lung Adenocarcinomas Is Associated with Cigarette SmokingThe American Journal of Surgical Pathology, 1993
- The relationship of p53 immunostaining to survival in carcinoma of the lungBritish Journal of Cancer, 1992
- p53: the ultimate tumor suppressor gene?The FASEB Journal, 1992
- Basal cell (basaloid) carcinoma of the lung: A new morphologic and phenotypic entity with separate prognostic significanceHuman Pathology, 1992
- ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutationCell, 1992
- Neuroendocrine Tumors of the Lung With Proposed Criteria for Large-Cell Neuroendocrine CarcinomaThe American Journal of Surgical Pathology, 1991
- Increased expression of mutant forms of p53 oncogene in primary lung cancerThe Lancet, 1990
- p53: A Frequent Target for Genetic Abnormalities in Lung CancerScience, 1989
- Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extractionAnalytical Biochemistry, 1987
- Isolation of human‐p53‐specific monoclonal antibodies and their use in the studies of human p53 expressionEuropean Journal of Biochemistry, 1986